Clinical introduction of the Tandemheart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention

BACKGROUND: In patients with poor left ventricular function and high-risk coronary lesions, prolonged ischemia during percutaneous coronary intervention (PCI) may have major hemodynamic consequences. The Tandemheart is a percutaneous left ventricular assist device intended for short-term circulatory support. METHODS AND RESULTS: The Tandem-heart incorporates 9-17 F. arterial cannulae and a unique 21 F. transseptal cannula and centrifugal bloodpump. Operating at 7500 rpm, the pump withdraws oxygenated blood from the left atrium and delivers up to 4 liters/min to the arterial circulation. As of May 2001, the Tandem-heart was electively employed in three male patients (ages 52, 54 and 56) scheduled for high-risk PCI. The mean time to initial circulatory support was less than 30 minutes. Systemic hemodynamics significantly improved prior to PCI in two patients. Pump flow after one hour ranged from 2.43 to 3.8 liters/min (mean 3.17 liters/min) and duration of support from 23 to 49 hours (mean 33 hours). Procedural success was 100%, with no significant hemolysis or bleeding. Successful weaning was completed in all patients, who have remained free of major cardiac events up to seven months post-PCI. CONCLUSIONS: In this first clinical experience of elective use of Tandem-heart for circulatory support during high-risk PCI, the device was easily inserted and preserved hemodynamic stability, regardless of the intrinsic cardiac function, creating optimism for more widespread use for this and other indications.

[1]  J. Dubois-Randé,et al.  Clinical experience with the percutaneous hemopump during high-risk coronary angioplasty. , 1998, The American journal of cardiology.

[2]  W. O’Neill,et al.  Comparison of acute results of prophylactic intraaortic balloon pumping with cardiopulmonary support for percutaneous transluminal coronary angioplasty (PCTA) , 1998, Catheterization and cardiovascular diagnosis.

[3]  A. Pavie,et al.  Left centrifugal pump cardiac assist with transseptal percutaneous left atrial cannula. , 1998, Artificial organs.

[4]  J. Dubois-Randé,et al.  Effects of the 14F hemopump on coronary hemodynamics in patients undergoing high-risk coronary angioplasty. , 1998, American heart journal.

[5]  S. Smith,et al.  Anterograde perfusion in acute limb ischemia secondary to vascular occlusive cardiopulmonary support. , 1995, Catheterization and cardiovascular diagnosis.

[6]  S. Sahay,et al.  Coronary angioplasty in high risk patients: comparison of elective intraaortic balloon pump and percutaneous cardiopulmonary bypass support--a randomized study. , 1995, Journal of interventional cardiology.

[7]  P. Teirstein,et al.  Prophylactic versus standby cardiopulmonary support for high risk percutaneous transluminal coronary angioplasty. , 1993, Journal of the American College of Cardiology.

[8]  R. Emery,et al.  The Nimbus Hemopump: a new left ventricular assist device that combines myocardial protection with circulatory support. , 1990, The Journal of invasive cardiology.

[9]  J M Fuqua,et al.  First human use of the Hemopump, a catheter-mounted ventricular assist device. , 1990, The Annals of thoracic surgery.

[10]  M. Domanski,et al.  Percutaneous cardiopulmonary bypass support in high-risk patients undergoing percutaneous transluminal coronary angioplasty. , 1989, The American journal of cardiology.

[11]  J M Fuqua,et al.  Clinical experience with the Hemopump. , 1989, ASAIO transactions.

[12]  R. Vogel The Maryland experience: angioplasty and valvuloplasty using percutaneous cardiopulmonary support. , 1988, The American journal of cardiology.